As the European markets navigate a period of volatility, with the STOXX Europe 600 Index showing little change amid global tech stock weakness and geopolitical tensions, investors are increasingly focused on companies that demonstrate resilience and potential for growth. In this environment, growth companies with high insider ownership can offer unique insights into management confidence and alignment with shareholder interests, making them noteworthy contenders in a fluctuating market landscape.
| Name | Insider Ownership | Earnings Growth |
| Kuros Biosciences (SWX:KURN) | 26.1% | 58.4% |
| KebNi (OM:KEBNI B) | 11.8% | 90.9% |
| Hacksaw (OM:HACK) | 13.2% | 23.9% |
| Dellia Group (OB:DELIA) | 29.9% | 47.9% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.7% | 73.9% |
| CD Projekt (WSE:CDR) | 35.2% | 29.7% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.8% |
| BioArctic (OM:BIOA B) | 32.2% | 53.3% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 50.2% |
Let's explore several standout options from the results in the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pharma Mar, S.A. is a biopharmaceutical company engaged in the research, development, production, and commercialization of bio-active principles for oncology across various international markets with a market cap of €1.32 billion.
Operations: The company's revenue from its oncology segment amounts to €221.93 million.
Insider Ownership: 12%
Pharma Mar is experiencing significant earnings growth, forecasted at 32.36% annually, surpassing the Spanish market's average. Despite high volatility in its share price recently, the company trades well below its estimated fair value and analysts expect a potential price increase of 37.6%. Recent European Commission approval for Zepzelca with atezolizumab as SCLC therapy highlights promising product developments, potentially enhancing Pharma Mar's growth prospects amidst substantial insider ownership.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Sivers Semiconductors AB (publ) operates through its subsidiaries to develop, manufacture, and sell chips, components, modules, and subsystems across North America, Europe, and Asia with a market cap of approximately SEK12.11 billion.
Operations: The company's revenue is primarily derived from its Wireless segment, which generated SEK204.54 million, and its Photonics segment, contributing SEK85.02 million.
Insider Ownership: 22.1%
Sivers Semiconductors is positioned for substantial growth, with revenue projected to increase by 31.8% annually, outpacing the Swedish market. The company has secured an $8.2 million order from ALL.SPACE and extended its Electronic Warfare project, highlighting strong demand in satellite communications and defense sectors. Despite recent volatility and a net loss of SEK 42.7 million in Q1 2026, Sivers' strategic alliances bolster its AI infrastructure capabilities, while insider ownership remains significant amidst board changes.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Verve Group Media SE is a digital media company that provides ad-software solutions in North America and Europe, with a market cap of €266.36 million.
Operations: The company's revenue is derived from Demand Side Platforms (DSP) at €168.15 million and Supply Side Platforms (SSP) at €477.89 million.
Insider Ownership: 26.7%
Verve Group Media is undergoing strategic transformations, including relocating its headquarters to Ireland and changing auditors to Deloitte. Despite a recent SDAX index removal, the company is poised for growth with expected annual revenue increases of 10.6%, outpacing the German market. Insiders have shown confidence through substantial share purchases in recent months, although interest coverage remains a concern. Verve's innovative retail media solutions position it well within the competitive ad-tech landscape, particularly in Germany's fragmented grocery sector.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com